Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $27K fell 69.0% year over year, behind the -23.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 59.1% from the prior quarter. Over 3 fiscal years it compounded at -13.8% a year.
Context
- Depreciation & amortization amounted to 0.5% of revenue in FY2025.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -69.0% toward the trailing-twelve-month pace of -23.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 325K USD
- Year-over-year change
- -5.2%
- 4-year CAGR
- +12.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 325K | -5.2% |
| FY2024 | 2024-12-31 | 343K | -21.5% |
| FY2023 | 2023-12-31 | 437K | -14.0% |
| FY2022 | 2022-12-31 | 508K | +147.8% |
| FY2021 | 2021-12-31 | 205K | — |
Depreciation & Amortization vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -23.0% is the 8th highest of 11, against a peer median of -13.1%.
- Over three fiscal years its annual growth of -13.8% compares with a peer median of +0.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.54M USD | -16.0% | -1.1% | 3350.2% | |
| LTM Mar 2026 | $4.93M USD | +55.9% | +19.6% | 7.1% | |
| LTM Mar 2026 | $3.62M USD | +20.6% | -8.0% | 24.9% | |
| LTM Mar 2026 | $3.13M USD | -28.6% | +0.0% | 27.9% | |
| FY2025 | €2.8M EUR | -46.2% | +47.6% | 62.4% | |
| LTM Mar 2026 | $2.79M USD | -10.3% | +0.1% | 9.9% | |
| LTM Mar 2026 | $786.79K USD | +70.5% | +36.1% | — | |
| LTM Mar 2026 | $265K USD | -23.0% | -13.8% | — | |
| LTM Mar 2026 | $226K USD | -16.3% | +27.5% | 383.1% | |
| LTM Mar 2026 | $103K USD | +0.0% | -11.6% | 0.2% | |
| LTM Mar 2026 | $42K USD | -31.1% | -31.1% | — | |
| Peer median (excluding BDTX) | — | -13.1% | +0.1% | 26.4% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 70M |
| Cost of Revenue | 0 | 0 | 437K | 0 | 325K |
| Gross Profit | 0 | 0 | (437K) | 0 | 69.68M |
| Gross Margin | — | — | — | — | 99.5% |
| Research & Development | 96.83M | 64.44M | 58.91M | 51.31M | 33.56M |
| Selling, General & Admin | 30.04M | 28.39M | 27.11M | 27.47M | 16.57M |
| Operating Expenses | 126.87M | 92.83M | 86.02M | 78.78M | 49.81M |
| Depreciation & Amortization | 205K | 508K | 437K | 343K | 325K |
| EBITDA | (125.39M) | (90.66M) | (82.01M) | (69.33M) | 22.69M |
| EBITDA Margin | — | — | — | — | 32.4% |
| Operating Income | (126.87M) | (92.83M) | (86.46M) | (78.78M) | 19.87M |
| Operating Margin | — | — | — | — | 28.4% |
| Interest Income | 3.46M | 2.03M | 1.92M | 2.18M | 4.06M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.28M | 1.66M | 4.02M | 9.11M | 2.5M |
| Income Before Tax | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Pre-Tax Margin | — | — | — | — | 32.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Net Margin | — | — | — | — | 32.0% |
| EPS (Basic) | (3.47) | (2.52) | (1.88) | (1.27) | 0.39 |
| EPS (Diluted) | (3.47) | (2.52) | (1.88) | (1.27) | 0.39 |
| Weighted Avg Shares | 36.19M | 36.23M | 43.95M | 55.03M | 56.87M |
| Weighted Avg Shares (Diluted) | 36.19M | 36.23M | 43.95M | 55.03M | 57.56M |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.